{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:10:28Z","timestamp":1791051028218,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.bcp.2009.10.025","type":"journal-article","created":{"date-parts":[[2009,11,7]],"date-time":"2009-11-07T10:11:14Z","timestamp":1257588674000},"page":"880-887","source":"Crossref","is-referenced-by-count":117,"title":["Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model"],"prefix":"10.1016","volume":"79","author":[{"given":"Jun-Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bora","family":"Inceoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Ulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipavan","family":"Chiamvimonvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2009.10.025_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4049\/jimmunol.178.2.641","article-title":"Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation","volume":"178","author":"Levick","year":"2007","journal-title":"J Immunol"},{"issue":"Suppl.","key":"10.1016\/j.bcp.2009.10.025_bib2","first-page":"66","article-title":"The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain","volume":"57","author":"Sciulli","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bcp.2009.10.025_bib3","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.2174\/138161205774370753","article-title":"Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer","volume":"11","author":"Claria","year":"2005","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bcp.2009.10.025_bib4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1126\/science.303.5660.941a","article-title":"Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation","volume":"303","author":"Wickelgren","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bcp.2009.10.025_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/156800906778742451","article-title":"Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention","volume":"6","author":"Chen","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2009.10.025_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tips.2007.11.006","article-title":"What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases","volume":"29","author":"Evans","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.10.025_bib7","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1164\/ajrccm.157.6.mar4","article-title":"Cell biology of the 5-lipoxygenase pathway","volume":"157","author":"Peters-Golden","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.bcp.2009.10.025_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.1144346","article-title":"Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein","volume":"317","author":"Ferguson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcp.2009.10.025_bib9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature05936","article-title":"Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis","volume":"448","author":"Ago","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2009.10.025_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0223-5234(03)00115-6","article-title":"Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs","volume":"38","author":"Charlier","year":"2003","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bcp.2009.10.025_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.bcp.2009.10.025_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-6147(00)01472-3","article-title":"New role for epoxyeicosatrienoic acids as anti-inflammatory mediators","volume":"21","author":"Campbell","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bcp.2009.10.025_bib13","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2009.10.025_bib14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bcp.2009.10.025_bib15","doi-asserted-by":"crossref","first-page":"F496","DOI":"10.1152\/ajprenal.00350.2004","article-title":"Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases","volume":"289","author":"Imig","year":"2005","journal-title":"Am J Physiol-Renal"},{"key":"10.1016\/j.bcp.2009.10.025_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1389200043335603","article-title":"Role of cytochrome P450 metabolites of arachidonic acid in hypertension","volume":"5","author":"Sarkis","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bcp.2009.10.025_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.prostaglandins.2006.05.017","article-title":"Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia\/reperfusion injury","volume":"82","author":"Seubert","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bcp.2009.10.025_bib18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pharmthera.2005.05.011","article-title":"Cytochrome P450 enzymes: Central players in cardiovascular health and disease","volume":"112","author":"Elbekai","year":"2006","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.bcp.2009.10.025_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1358\/dof.2005.030.03.884303","article-title":"P-450: a new target in the heart and coronary circulation","volume":"30","author":"Doggrell","year":"2005","journal-title":"Drug Future"},{"key":"10.1016\/j.bcp.2009.10.025_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2004.10.001","article-title":"Epoxide hydrolases: their roles and interactions with lipid metabolism","volume":"44","author":"Newman","year":"2005","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.bcp.2009.10.025_bib21","doi-asserted-by":"crossref","first-page":"A669","DOI":"10.1096\/fasebj.20.4.A669","article-title":"Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition","volume":"20","author":"Morisseau","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2009.10.025_bib22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.HYP.0000176237.74820.75","article-title":"An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension","volume":"46","author":"Imig","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.10.025_bib23","first-page":"A418","article-title":"Soluble epoxide hydrolase regulates renal microvascular angiotensin II reactivity in hypertension","volume":"16","author":"Zhao","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2009.10.025_bib24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.10.025_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1527-3466.2006.00169.x","article-title":"Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors","volume":"24","author":"Imig","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.bcp.2009.10.025_bib26","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1073\/pnas.0503279102","article-title":"Soluble epoxide hydrolase is a therapeutic target for acute inflammation","volume":"102","author":"Schmelzer","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2009.10.025_bib27","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1073\/pnas.0409591102","article-title":"Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor","volume":"102","author":"Smith","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2009.10.025_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1042\/CS20080039","article-title":"Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats","volume":"116","author":"Olearczyk","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.bcp.2009.10.025_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2006.05.004","article-title":"Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs)","volume":"82","author":"Inceoglu","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bcp.2009.10.025_bib30","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/01.ATV.0000242013.29441.81","article-title":"Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1","volume":"26","author":"Ng","year":"2006","journal-title":"Arterioscler Thromb Vasc"},{"key":"10.1016\/j.bcp.2009.10.025_bib31","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1073\/pnas.0605908103","article-title":"Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors","volume":"103","author":"Schmelzer","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2009.10.025_bib32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000237390.92932.37","article-title":"Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function","volume":"99","author":"Seubert","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.bcp.2009.10.025_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.105.091876","article-title":"Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition","volume":"316","author":"Davis","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2009.10.025_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1096\/fj.05-4341fje","article-title":"Cytochrome P450 epoxygenases provide a novel mechanism for penile erection","volume":"20","author":"Jin","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2009.10.025_bib35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jacc.2006.03.053","article-title":"Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation","volume":"48","author":"Borgdorff","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bcp.2009.10.025_bib36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1203\/01.PDR.0000161415.62776.0A","article-title":"Selective inhibitors differentially affect cyclooxygenase-dependent pial arteriolar responses in newborn pigs","volume":"57","author":"Domoki","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.bcp.2009.10.025_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.bjp.0701869","article-title":"Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone","volume":"124","author":"Leach","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2009.10.025_bib38","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/nm1202-802","article-title":"Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics","volume":"8","author":"Brindle","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2009.10.025_bib39","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1172\/JCI35111","article-title":"Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury","volume":"118","author":"Lewis","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.10.025_bib40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/14622416.6.7.691","article-title":"The consortium for metabonomic toxicology (COMET): aims, activities and achievements","volume":"6","author":"Lindon","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bcp.2009.10.025_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1013713905833","article-title":"Metabolomics\u2014the link between genotypes and phenotypes","volume":"48","author":"Fiehn","year":"2002","journal-title":"Plant Mol Biol"},{"key":"10.1016\/j.bcp.2009.10.025_bib42","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1172\/JCI34138","article-title":"Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques","volume":"118","author":"Wikoff","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.10.025_bib43","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1021\/ac901282n","article-title":"Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry","volume":"81","author":"Yang","year":"2009","journal-title":"Anal Chem"},{"key":"10.1016\/j.bcp.2009.10.025_bib44","doi-asserted-by":"crossref","first-page":"40504","DOI":"10.1074\/jbc.M008106200","article-title":"Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation","volume":"275","author":"Sinal","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.10.025_bib45","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1074\/jbc.M608057200","article-title":"Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice","volume":"282","author":"Luria","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.10.025_bib46","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1021\/jm070270t","article-title":"Orally bioavailable potent soluble epoxide hydrolase (sEH) inhibitors","volume":"50","author":"Hwang","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2009.10.025_bib47","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/01.CIR.0000027816.54430.96","article-title":"Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice","volume":"106","author":"Cyrus","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2009.10.025_bib48","first-page":"R52","article-title":"Evidence supporting involvement of leukotrienes in LPS-induced hypothermia in mice","volume":"276","author":"Paul","year":"1999","journal-title":"Am J Physiol-Reg I"},{"key":"10.1016\/j.bcp.2009.10.025_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1476-5381.2008.00009.x","article-title":"Pharmacokinetic optimization of four soluble epoxide hydrolase (sEH) inhibitors for use in a murine model of inflammation","volume":"156","author":"Liu","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2009.10.025_bib50","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1158\/1535-7163.MCT-09-0119","article-title":"Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo","volume":"8","author":"Liu","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.10.025_bib51","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1096\/fasebj.6.2.1537463","article-title":"Cytochrome-P450 and the Arachidonate Cascade","volume":"6","author":"Capdevila","year":"1992","journal-title":"FASEB J"},{"key":"10.1016\/j.bcp.2009.10.025_bib52","first-page":"205","article-title":"Lipopolysaccharide, tumor-necrosis-factor, and interleukin-1 interact to cause hypotension","volume":"120","author":"Weinberg","year":"1992","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.bcp.2009.10.025_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1172\/JCI1368","article-title":"IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses","volume":"101","author":"Xing","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.10.025_bib54","doi-asserted-by":"crossref","first-page":"A396","DOI":"10.1289\/ehp.112-1241997","article-title":"Metabolomics\u2014a new exciting field within the \u201comics\u201d sciences","volume":"112","author":"Dettmer","year":"2004","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.bcp.2009.10.025_bib55","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000264498.60702.0d","article-title":"5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation","volume":"100","author":"Back","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.bcp.2009.10.025_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2362.2006.01606.x","article-title":"Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE\/LDLR-double knockout mice","volume":"36","author":"Jawien","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.bcp.2009.10.025_bib57","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1189\/jlb.1204747","article-title":"Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells","volume":"78","author":"Titos","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bcp.2009.10.025_bib58","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1084\/jem.185.6.1065","article-title":"Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses","volume":"185","author":"Byrum","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.bcp.2009.10.025_bib59","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1172\/JCI118696","article-title":"Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats","volume":"97","author":"Voelkel","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.10.025_bib60","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/1535-7163.MCT-06-0318","article-title":"Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells","volume":"5","author":"Cianchi","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2009.10.025_bib61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0304-3959(97)00128-0","article-title":"Ketorolac potentiates morphine in postoperative patient-controlled analgesia","volume":"73","author":"Picard","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2009.10.025_bib62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1503\/cmaj.070186","article-title":"Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding","volume":"177","author":"Delaney","year":"2007","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.bcp.2009.10.025_bib63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-104-3-390","article-title":"Aspirin and the stomach","volume":"104","author":"Graham","year":"1986","journal-title":"Ann Intern Med"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629520900940X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629520900940X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:12:37Z","timestamp":1634145157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629520900940X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S000629520900940X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.10.025","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}